RFA-DK-16-029: NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01)
LOI: November 14, 2016, 5pm PDT
Internal Deadline: September 16, 2016, 5pm
External Deadline: December 14, 2016, 5pm
Type: Cooperative Agreement
Estimated Number of Awards: 6
Anticipated Amount: Application budgets are limited to $293,000 (direct costs) per year.
Cost Sharing: This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Submission Process: PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://app.wizehive.com/webform/USCgrants
Materials to submit:
- Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt.).
- CV – (5 pages maximum)
Who May Serve as PI: Standard NIH requirements.
The goal of the research to be carried out by the IBDGC is the enhancement of our understanding of the pathophysiologic mechanisms of IBD. This enhanced understanding will lead to improved methods for diagnosis, prevention, and treatment of IBD. Activities appropriate for the GRCs include the following examples, as well as others not mentioned in this list:
- Recruitment and phenotypic evaluation of IBD patients, affected and unaffected relatives, and unrelated healthy controls
- Recruitment and phenotypic evaluation of subjects from minority populations (e.g., African-American, Ashkenazic Jewish)
- Genome-wide and selective genotyping of DNA from recruited subjects
- Whole-exome and whole-genome sequencing, and targeted resequencing of DNA from recruited subjects
- Epigenomic, transcriptomic, proteomic, and metabolomic analyses of relevant tissue samples from recruited subjects, and systems biology analyses of the resulting data
- Analyses of the composition and activities of the intestinal microbiome of recruited subjects.
- Screening of candidate genes and genetic variants in gut barrier, mucosal immune, and other physiological domains, using cultured cells, organoids, Drosophila, zebrafish, mice, and other assay platforms
- Analyses of the relationships among host genetic variation, intestinal microbiome composition and activity, and variation in the presentation, severity, natural history, and response to treatment of IBD.
- Elucidation of regulatory interactions between DNA sites within the known IBD susceptibility loci and other genes, regardless of their genomic location
- Reanalysis of existing data with novel analytic approaches to identify previously unknown susceptibility loci.
Visit our Institutionally Limited Submission webpage for updates and other announcements.